Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

Clinical Utility of Cystatin C in the Early Detection of Contrast Induced Acute Kidney Injury

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07197957

Enrollment

100

Registered

2025-09-30

Start date

2025-03-11

Completion date

2027-02-28

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).

Detailed description

The primary objective of this study is to evaluate the clinical utility of Cystatin C in early detection of contrast-induced AKI. To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects ages 18 years and above * Inpatients with CKD (Figure 1) * Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media. * Pre and post contrast available * All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.

Exclusion criteria

* Preexisting dialysis * Patients under the age of 18 years * Pregnancy * Incarcerated individuals * Patients with impaired cognition and unable to follow consent procedures * Recent exposure to CM (within 2 days before/after procedure) * Cardiac shock * Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim

Design outcomes

Primary

Measure	Time frame
Incidence of AKI when sCr is used compared to when sCyC is used 24-48 hours after contract media and at 7-10 days follow-up	10 days

Secondary

Measure	Time frame
Change from baseline in eGFRcr compared to change from baseline in eGFRcys 24-48 hours after contrast media and at 7 to 10 days follow-up	10 days

Countries

United States

Contacts

Primary ContactTracy Johns, PharmD

tracy.johns@baycare.org727-519-1310

Outcome results